"Wir schaffen global führende Biotechs mit europäischen Wurzeln"
In a recent Plattform Life Sciences interview, Forbion General Partner Dr. Dmitrij Hristodorov outlined how Forbion is shaping the next generation of globally leading biotech companies with European roots. With more than €5 billion in assets under management, Forbion combines early-stage venture creation with later-stage and crossover investing, building and scaling companies that are anchored in scientific excellence and long-term value creation.
Dr. Hristodorov emphasized that Forbion’s disciplined approach focuses on sound science, clinical quality, and sustainable growth, rather than short-term market sentiment. Europe, he noted, offers world-class research and entrepreneurial talent, but still requires stronger translational ecosystems and access to growth capital to fully compete on a global scale.
By expanding its transatlantic footprint and supporting portfolio companies across all stages of development, Forbion aims to bridge this gap, enabling European innovation to thrive internationally. As Dr. Hristodorov concluded, Forbion’s mission is to turn scientific breakthroughs into enduring global leaders that deliver meaningful impact for patients and investors alike.
Ein Drittel unseres Portfolios besteht aus Unternehmen, die wir selbst gründen oder aufbauen, oft zusammen mit erfahrenen Unternehmern und innovativen oder einlizenzierten Assets.
Dmitrij Hristodorov, PhD
General Partner